SCHEMBL15034065

SCHEMBL15034065

COc1nc(C(=O)N2CCN(C(=O)c3ncn(-c4cccc(Cl)c4)n3)C(C)(C)C2)cc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.38
MAPT P10636 4/20 0.38
POLB P06746 3/20 0.38
CCKAR P32238 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
MGLL Q99685 3/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
NOD2 Q9HC29 1/20 0.35
TSHR P16473 2/20 0.35
NPC1 O15118 1/20 0.35
ALOX15 P16050 1/20 0.35
SLC6A7 Q99884 1/20 0.35
MPO P05164 1/20 0.34
GRM5 P41594 2/20 0.34
NOTUM Q6P988 1/20 0.33
TACR3 P29371 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034116 0.93 CFTR (0.42) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034058 0.92 MAPT (0.35) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034055 0.92 CCKAR (0.39) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034044 0.91 MGLL (0.37) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034109 0.91 TSHR (0.35) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034059 0.91 CFTR (0.40) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034108 0.90 CNR2 (0.37) MGLL
SCHEMBL15020101 0.89 CFTR (0.37) CFTRCCKARMGLLLMNAGRM5
SCHEMBL15034103 0.87 MAPT (0.42) CFTRMAPTPOLBCCKARSMN1; SMN2
SCHEMBL15034204 0.87 CFTR (0.37) CFTRMAPTPOLBCCKARSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 CFTR 3753/4885MAPT 270/4885POLB 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.